CSIMarket Company Name, Ticker, Customers, else..
 
Lucira Health Inc   (NASDAQ: LHDX)
Other Ticker:  
 
 
Price: $0.0000 $0.00 %
Day's High: 0.00 Week Perf:
Day's Low: $ 0.00 30 Day Perf:
Volume (M): 0 52 Wk High: $ 0.00
Volume (M$): $ 0 52 Wk Avg: $0.00
Open: $0.00 52 Wk Low: $0.00



 Market Capitalization (Millions $) -
 Shares Outstanding (Millions) 40
 Employees 100
 Revenues (TTM) (Millions $) 212
 Net Income (TTM) (Millions $) -143
 Cash Flow (TTM) (Millions $) -78
 Capital Exp. (TTM) (Millions $) 26

Lucira Health Inc
Lucira Health Inc.
is a medical technology company based in the United States that focuses on developing and commercializing innovative technologies for healthcare providers and consumers.
The company specializes in the areas of molecular diagnostics, mobile health, and medical devices.
The company is best known for its Lucira Check-It COVID-19 At-Home Test Kit, a single-use, molecular test designed to detect the presence of the virus that causes COVID-19.The Lucira Check-It COVID-19 At-Home Test Kit is a portable, quick, and easy-to-use at-home test that helps individuals self-diagnose COVID-19 within 30 minutes.
The test is authorized for emergency use in the United States by the Food and Drug Administration (FDA) under an Emergency Use Authorization (EUA) and is the first COVID-19 test that is fully self-contained, enabling users to complete the entire testing process at home without needing to send their samples to a laboratory.Lucira Health Inc.
was founded in 2013 and is headquartered in Emeryville, California.
The company has partnerships with several healthcare and biotech companies, including Abbott and JSR Life Sciences, to optimize its diagnostic technology and expand its market reach.
In addition to its COVID-19 test, the company is also developing other diagnostic products that focus on infectious diseases, cancer, and women's health.


   Company Address: 1412 62nd Street Emeryville 94608 CA
   Company Phone Number: 350-8071   Stock Exchange / Ticker: NASDAQ LHDX


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Aspira Women S Health Inc

AWH Reports Remarkable Revenue Surge from July to September 30, 2024!

Aspira Women S Health Inc saw eps improvement to $-0.23 in the July to September 30 2024 period, Revenue increased by 9.653 % to $2.43 million in comparison to $2.22 million in the prior year financial reporting period. Aspira Women S Health Inc s' top-line grew at higher rate in contrast to the the revenue at nearly all of the In Vitro and In Vivo Diagnostic Substances industry contemporaries, in the third quarter of 2024 the two third corporations in In Vitro and In Vivo Diagnostic Substances sectors made the top-line improvement of 5.70% relative to the corresponding period a year ago.

Tnf Pharmaceuticals Inc

TNF Pharmaceuticals Inc. Shows Promising Stock Market Impact with Significant Fiscal Improvement Despite Recent Operating Loss of $1.83 Million

The In Vitro and In Vivo Diagnostic Substances sector veterans begin to analyze the third quarter of 2024 earnings. Presently they follow operating loss of $-1.825639 million, from the TNFA, as it has not mentioned any revenue yet, for the own July to September 30 2024 reporting season.

Biomerica Inc

The In Vitro and In Vivo Diagnostic Substances company reported a modest rise, in the most recent fiscal period

For the first quarter of 2025 earnings season company increased a deficit per share of $-0.08 per share compare to $-0.07 a year before and surged deficit from $-0.07 per share from the preceding reporting season. The Revenue grew by 5.487 % to $1.81 million from $1.71 million in the same reporting season a year before and sequentially revenue surged by 61.628 % from $1.12 million. Yet the Biomerica Inc s' revenue gain below theIn Vitro and In Vivo Diagnostic Substances industry contemporaries, had an average 5.70% from the first quarter of 2024 revenue rise.

Volitionrx Limited

Vanishing Deficit at the company in third quarter of 2024

For the third quarter of 2024 Volitionrx Limited decreased a loss per share of $-0.07 per share compare to $-0.11 a year ago and earnings per share improved from $-0.08 per share from the preceding reporting season. The revenue increased sharply by 187.222 % to $0.47 million from $0.17 million in the corresponding reporting season a year ago and sequentially revenue improved by 19.89 % from $0.40 million. In Vitro and In Vivo Diagnostic Substances company's revenue advanced faster compared to the the top-line at nearly all of the In Vitro and In Vivo Diagnostic Substances sector contemporaries, in the third quarter of 2024 the two third companies in In Vitro and In Vivo Diagnostic Substances sectors made the revenue rise of 5.67% from the corresponding reporting season a year ago.

Cardio Diagnostics Holdings Inc

The In Vitro and In Vivo Diagnostic Substances company announced it had very pressing period, in the third quarter of 2024 earnings season

For the July to September 30 2024 financial time-frame company Losses have swelled of $-0.06 per share compare to $0.00 a year ago and from $-0.06 per share from the prior reporting season. The revenue faded by -34.397 % to $0.01 million from $0.01 million in the similar reporting season a year ago and sequentially revenue fell by -16.391 % from $0.01 million.










Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com